Cargando…

Tumour budding with and without admixed inflammation: two different sides of the same coin?

BACKGROUND: Tumour budding is an adverse prognostic indicator in colorectal cancer (CRC). Marked overall peritumoural inflammation has been associated with favourable outcome and may lead to the presence of isolated cancer cells due to destruction of invading cancer cell islets. METHODS: We assessed...

Descripción completa

Detalles Bibliográficos
Autores principales: Max, Nicole, Harbaum, Lars, Pollheimer, Marion J, Lindtner, Richard A, Kornprat, Peter, Langner, Cord
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815770/
https://www.ncbi.nlm.nih.gov/pubmed/26766735
http://dx.doi.org/10.1038/bjc.2015.454
_version_ 1782424622300397568
author Max, Nicole
Harbaum, Lars
Pollheimer, Marion J
Lindtner, Richard A
Kornprat, Peter
Langner, Cord
author_facet Max, Nicole
Harbaum, Lars
Pollheimer, Marion J
Lindtner, Richard A
Kornprat, Peter
Langner, Cord
author_sort Max, Nicole
collection PubMed
description BACKGROUND: Tumour budding is an adverse prognostic indicator in colorectal cancer (CRC). Marked overall peritumoural inflammation has been associated with favourable outcome and may lead to the presence of isolated cancer cells due to destruction of invading cancer cell islets. METHODS: We assessed the prognostic significance of tumour budding and peritumoural inflammation in a cohort of 381 patients with CRC applying univariate and multivariate analyses. RESULTS: Patients with high-grade budding and marked inflammation had a significantly better outcome compared with patients with high-grade budding and only mild inflammation. Outcome in these cases, however, was still worse compared with cases with low-grade budding, in which the extent of peritumoural inflammation had no further prognostic effect. CONCLUSIONS: Tumour budding proved to be a powerful prognostic variable in patients with CRC. Scattering of invading cancer cell islets by marked overall peritumoural inflammation seems to have a minor role.
format Online
Article
Text
id pubmed-4815770
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-48157702017-02-16 Tumour budding with and without admixed inflammation: two different sides of the same coin? Max, Nicole Harbaum, Lars Pollheimer, Marion J Lindtner, Richard A Kornprat, Peter Langner, Cord Br J Cancer Clinical Study BACKGROUND: Tumour budding is an adverse prognostic indicator in colorectal cancer (CRC). Marked overall peritumoural inflammation has been associated with favourable outcome and may lead to the presence of isolated cancer cells due to destruction of invading cancer cell islets. METHODS: We assessed the prognostic significance of tumour budding and peritumoural inflammation in a cohort of 381 patients with CRC applying univariate and multivariate analyses. RESULTS: Patients with high-grade budding and marked inflammation had a significantly better outcome compared with patients with high-grade budding and only mild inflammation. Outcome in these cases, however, was still worse compared with cases with low-grade budding, in which the extent of peritumoural inflammation had no further prognostic effect. CONCLUSIONS: Tumour budding proved to be a powerful prognostic variable in patients with CRC. Scattering of invading cancer cell islets by marked overall peritumoural inflammation seems to have a minor role. Nature Publishing Group 2016-02-16 2016-01-14 /pmc/articles/PMC4815770/ /pubmed/26766735 http://dx.doi.org/10.1038/bjc.2015.454 Text en Copyright © 2016 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Clinical Study
Max, Nicole
Harbaum, Lars
Pollheimer, Marion J
Lindtner, Richard A
Kornprat, Peter
Langner, Cord
Tumour budding with and without admixed inflammation: two different sides of the same coin?
title Tumour budding with and without admixed inflammation: two different sides of the same coin?
title_full Tumour budding with and without admixed inflammation: two different sides of the same coin?
title_fullStr Tumour budding with and without admixed inflammation: two different sides of the same coin?
title_full_unstemmed Tumour budding with and without admixed inflammation: two different sides of the same coin?
title_short Tumour budding with and without admixed inflammation: two different sides of the same coin?
title_sort tumour budding with and without admixed inflammation: two different sides of the same coin?
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815770/
https://www.ncbi.nlm.nih.gov/pubmed/26766735
http://dx.doi.org/10.1038/bjc.2015.454
work_keys_str_mv AT maxnicole tumourbuddingwithandwithoutadmixedinflammationtwodifferentsidesofthesamecoin
AT harbaumlars tumourbuddingwithandwithoutadmixedinflammationtwodifferentsidesofthesamecoin
AT pollheimermarionj tumourbuddingwithandwithoutadmixedinflammationtwodifferentsidesofthesamecoin
AT lindtnerricharda tumourbuddingwithandwithoutadmixedinflammationtwodifferentsidesofthesamecoin
AT kornpratpeter tumourbuddingwithandwithoutadmixedinflammationtwodifferentsidesofthesamecoin
AT langnercord tumourbuddingwithandwithoutadmixedinflammationtwodifferentsidesofthesamecoin